Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function

European Journal of Contraception and Reproductive Health Care

Volumn 16, Issue 6, 2011, Pages 458-467

  Ågren, Ulla M ^a,b   Anttila, Marjatta ^a   Mäenpää Liukko, Kristiina ^c   Rantala, Maija Liisa ^d   Rautiainen, Hilkka ^e   Sommer, Werner F ^f   Mommers, Ellen ^f  

^a FSHS Kuopio   (Finland)

^b MERCK ANIMAL HEALTH   (United States)

^c Turun Gynekologikeskus Ky   (Finland)

^d Lääkärikeskus Adenova   (Finland)

^e Lääkärikeskus Gyneko Oy   (Finland)

^f MSD   (Netherlands)

Author keywords

17 oestradiol; Adrenal; Androgen; Nomegestrol acetate; Oral contraceptives; SHBG; Thyroid

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ESTRADIOL PLUS NOMEGESTROL ACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HYDROCORTISONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROTROPIN; THYROXINE BINDING GLOBULIN; TRANSCORTIN;

ACNE; ADRENAL FUNCTION; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE FUNCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; INTERMETHOD COMPARISON; LEG PAIN; LIMB WEAKNESS; MITRAL VALVE DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SIDE EFFECT; TACHYCARDIA; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTRADIOL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYDROCORTISONE; LEVONORGESTREL; MEGESTROL; MIDDLE AGED; NORPREGNADIENES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE CONGENERS; THYROXINE-BINDING GLOBULIN; TRANSCORTIN; YOUNG ADULT;

EID: 80955130105     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2011.614363     Document Type: Conference Paper

References (29)

1. United Nations Department of Economic and Social Affairs Population Division. World contraceptive use 2007. Accessed 5 August 2009 from: http://www. un.org/esa/population/publications/contraceptive2007/ contraceptive-2007-table. pdf
2. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57:211-30. (Pubitemid 29281907)
3. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-7.
4. Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436-44.
5. Palacios S, Wildt L, Parke S, et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A phase III trial. Eur J Obstet Gynecol Reprod Biol 2010;149:57-62.
6. Astedt B, Jeppsson S, Liedholm P, et al. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17beta-oestradiol. Br J Obstet Gynaecol 1979; 86:732-6. (Pubitemid 9245029)
7. Serup J, Bostofte E, Larsen S, Westergaard J. Effectivity and acceptability of oral contraceptives containing natural and artifi cial estrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet Gynecol Scand 1981;60:203-6. (Pubitemid 11113403)
8. Wenzl R, Bennink HC, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17beta-estradiol. Fertil Steril 1993;60:616-9. (Pubitemid 23298503)
9. Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17[beta]-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception 1996;54:333-38. (Pubitemid 26412416)
10. Calaf i Alsina JC. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:1-3.
11. Lello S. Nomegestrol acetate: Pharmacology, safety profi le and therapeutic efficacy. Drugs 2010;70:541-59.
12. Duijkers IJ, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care 2010;15:314-25.
13. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41:345-52. (Pubitemid 20134343)
14. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 2003;67:361-6. (Pubitemid 36556225)
15. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32. (Pubitemid 36084284)
16. Ågren UM, Anttila M, Mäenpää -Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444-57.
17. World Health Organization Medical eligibility criteria for contraceptive use, 4th edn. Geneva: WHO Press 2009: 1-121. Accessed 22 June 2011 from: http://whqlibdoc. who.int/publications/2010/9789241563888-eng.pdf
18. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84: 3666-72. (Pubitemid 30645223)
19. Lehmann EL. N onparametrics: Statistical methods based on ranks Oakland, CA: Holden-Day, Inc. 1975:81-95.
20. Hammond GL, Langley MS, Robinson PA, et al. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril 1984;42:44-51. (Pubitemid 14086149)
21. Humpel M, Tuber U, Kuhnz W, et al. Comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. Horm Res 1990;33:35-9. (Pubitemid 20212124)
22. Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009;14:221-32.
23. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995;51:341-6.
24. Duijkers I, Killick S, Bigrigg A, Dieben TO. A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2004;9:131-40. (Pubitemid 39539574)
25. Kuhl H, Gahn G, Romberg G, et al. A randomized crossover comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters: II. Effects upon thyroid function, gastrin, STH, and glucose tolerance. Contraception 1985;32:97-107. (Pubitemid 15227622)
26. Sanger N, Stahlberg S, Manthey T, et al. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: Conventional vs. extended-cycle use. Contraception 2008;77:420-5.
27. Rich P. Hormonal contraceptives for acne management. Cutis 2008;81:13-8.
28. Davison SL, Bell RJ, LaChina M, et al. Sexual function in well women: Stratifi cation by sexual satisfaction, hormone use, and menopause status. J Sex Med 2008;5:1214-22. (Pubitemid 351606707)
29. Wierman ME, Nappi RE, Avis N, et al. Endocrine aspects of women ' s sexual function. J Sex Med 2010;7: 561-85.